Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy

Biotech Investing

Apellis Pharmaceuticals (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today will provide an update with 18-month data on its Phase 2 trial (FILLY) of its complement C3 inhibitor, APL-2, in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD). As quoted in the …

Apellis Pharmaceuticals (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today will provide an update with 18-month data on its Phase 2 trial (FILLY) of its complement C3 inhibitor, APL-2, in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD).

As quoted in the press release:

Rishi Singh, MD, Staff Surgeon at the Cole Eye Institute at the Cleveland Clinic, said, “The 18-month results of the FILLY trial support the positive effect seen at 12 months. In the FILLY trial, APL-2 significantly reduced the growth of GA, and may for the first time offer these patients hope of preserving their vision. We eagerly anticipate the start of the Phase 3 trials.”

Click here to read the full press release.

The Conversation (0)
Ă—